With over 25 years across Pfizer, Novartis, and healthcare investments, Tay brings deep expertise in rare diseases, gene therapy, oncology, and specialty medicines, spanning drug development, global access, and commercialisation in the US and internationally.

A former Executive Committee member at AveXis® (later Novartis Gene Therapies®), he pioneered the access and commercialisation model for Zolgensma® approved in over 50 countries, with more than 4,000 patients treated and $5B+ in cumulative revenue. Tay was also part of the founding team that led the first FDA approval and launch of Kymriah®, the world’s first CAR-T therapy.

Tay is also Managing General Partner of Renovamen Advisory® LLC and a Venture Partner at 4BIO Capital®, with a rare track record of successfully commercialising both AAV and CAR-T therapies globally. He supports early-stage biotech and investor teams at the intersection of scientific innovation, commercial execution, and business partnering to bring strategic clarity, executional insight, and global readiness to high-impact therapeutic platforms.

Tay is also a Fellow of the Alliance for Regenerative Medicine®, where he supports the executive team with sector insights on global access, commercialisation, and investor engagement. He holds a BSc in Management Sciences from Brunel University London and completed executive education in Venture Capital at Imperial College London.